Synthesis and structure–activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold
Ryan P. Wurz(Amgen (United States)), Mark H. Norman(Amgen (United States)), Nancy R. Zhang(University of the Arts), Nobuko Nishimura(Amgen (United States)), Kevin Yang(Revolution Medicines (United States)), Tisha San Miguel(Amgen (United States)), Douglas A. Whittington(Amgen (United States)), Erin L. Mullady(Amgen (United States)), Liping H. Pettus(Amgen (United States)), Jian Jiang(Xuzhou Medical College), Longbin Liu(National University of Defense Technology), Ling Wang(Guizhou University), Paul E. Hughes(Amgen (United States)), Sean Caenepeel(Amgen (United States)), Kristin L. Andrews(Amgen (United States)), Yunxin Bo(Amgen (United States)), John D. McCarter(Amgen (United States)), Daniel J. Freeman(Amgen (United States)), Raju Subramanian(Gilead Sciences (United States))
Cited by 30
Related Papers
Integrin activation controls metastasis in human breast cancer
|Proceedings of the National Academy of Sciences|2001|580
Glucuronidation of Statins in Animals and Humans: A Novel Mechanism of Statin Lactonization
|Drug Metabolism and Disposition|2002|346
Effects of Fibrates on Metabolism of Statins in Human Hepatocytes
|Drug Metabolism and Disposition|2002|325